Related Experiment Videos
Combination lipid therapy in type 2 diabetes mellitus
1Service Endocrinologie, Diabétologie et Maladies Métaboliques, Hôpital du Bocage, Dijon, France. bruno.verges@chu-dijon.fr
Expert Opinion on Pharmacotherapy
|February 18, 2011
Summary
Combination lipid therapy may help manage diabetic dyslipidemia, but more trials are needed to confirm its cardiovascular benefits in type 2 diabetes patients. This approach targets hypertriglyceridemia and low HDL-C.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Statins reduce cardiovascular risk in type 2 diabetes but do not fully address diabetic dyslipidemia.
- Diabetic dyslipidemia, characterized by hypertriglyceridemia and low HDL-C, persists as a high cardiovascular risk factor.
- Combination lipid therapy is explored to manage residual risk in these patients.
Purpose of the Study:
- To review the rationale for combination lipid therapy in type 2 diabetes.
- To assess the impact of various drugs on diabetic dyslipidemia and cardiovascular event prevention.
Main Methods:
- Literature review of studies on fibrates, pioglitazone, niacin, and omega-3 fatty acids.
- Analysis of drug effects on lipid profiles and cardiovascular outcomes in type 2 diabetes.
Main Results:
- Fibrates may benefit patients with hypertriglyceridemia and low HDL-C, though overall cardiovascular benefit is unclear.
- Pioglitazone demonstrated a reduction in major cardiovascular events in type 2 diabetes.
- Niacin and omega-3 fatty acids show promise for diabetic dyslipidemia but require further cardiovascular outcome trials.
Conclusions:
- Combination lipid therapy shows potential for controlling diabetic dyslipidemia.
- Further clinical trials are necessary to confirm the efficacy of these combined therapies in significantly reducing cardiovascular risk.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:36Carbohydrate Metabolism
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...